JP2020536097A - 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 - Google Patents

膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 Download PDF

Info

Publication number
JP2020536097A
JP2020536097A JP2020519138A JP2020519138A JP2020536097A JP 2020536097 A JP2020536097 A JP 2020536097A JP 2020519138 A JP2020519138 A JP 2020519138A JP 2020519138 A JP2020519138 A JP 2020519138A JP 2020536097 A JP2020536097 A JP 2020536097A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
week
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536097A5 (enExample
Inventor
ジュゼッペ レムッツィ，
ジュゼッペ レムッツィ，
ピエロ ルッジェネンティ，
ピエロ ルッジェネンティ，
シャン ガオ，
シャン ガオ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020536097A publication Critical patent/JP2020536097A/ja
Publication of JP2020536097A5 publication Critical patent/JP2020536097A5/ja
Priority to JP2023089908A priority Critical patent/JP2023101717A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020519138A 2017-10-04 2018-10-02 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与 Pending JP2020536097A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023089908A JP2023101717A (ja) 2017-10-04 2023-05-31 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568060P 2017-10-04 2017-10-04
US62/568,060 2017-10-04
US201862652615P 2018-04-04 2018-04-04
US62/652,615 2018-04-04
PCT/US2018/053976 WO2019070714A1 (en) 2017-10-04 2018-10-02 ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023089908A Division JP2023101717A (ja) 2017-10-04 2023-05-31 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与

Publications (2)

Publication Number Publication Date
JP2020536097A true JP2020536097A (ja) 2020-12-10
JP2020536097A5 JP2020536097A5 (enExample) 2021-11-04

Family

ID=64051671

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519138A Pending JP2020536097A (ja) 2017-10-04 2018-10-02 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
JP2023089908A Pending JP2023101717A (ja) 2017-10-04 2023-05-31 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023089908A Pending JP2023101717A (ja) 2017-10-04 2023-05-31 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与

Country Status (11)

Country Link
US (2) US20200262897A1 (enExample)
EP (2) EP3692064A1 (enExample)
JP (2) JP2020536097A (enExample)
KR (1) KR20200059279A (enExample)
CN (1) CN111278857A (enExample)
AU (1) AU2018345625A1 (enExample)
BR (1) BR112020006692A2 (enExample)
CA (1) CA3078362A1 (enExample)
CO (1) CO2020004831A2 (enExample)
MX (1) MX2020003619A (enExample)
WO (1) WO2019070714A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
WO2019227102A1 (en) * 2018-05-25 2019-11-28 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US12239645B2 (en) 2018-12-17 2025-03-04 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
JP7635138B2 (ja) 2019-03-22 2025-02-25 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
JP2022542430A (ja) * 2019-08-01 2022-10-03 ヤンセン バイオテツク，インコーポレーテツド Ｆｃｒｎ抗体およびその使用の方法
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2016209956A1 (en) * 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
JP2017512463A (ja) * 2014-03-07 2017-05-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 向上した薬物動態を有する抗ｃ５抗体
JP2017226655A (ja) * 2016-06-17 2017-12-28 中外製薬株式会社 抗ｃ５抗体および使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508262A (ja) * 2008-11-10 2012-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
JP2017512463A (ja) * 2014-03-07 2017-05-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 向上した薬物動態を有する抗ｃ５抗体
WO2016209956A1 (en) * 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
JP2017226655A (ja) * 2016-06-17 2017-12-28 中外製薬株式会社 抗ｃ５抗体および使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLIN. J. AM. SOC. NEPHROL.(2012) VOL.7, ISSUE 5, P.748-756, JPN6022031071, ISSN: 0004977526 *
NCT02093533 ECULIZUMABIN PRIMARY MPGN (EAGLE), CLINICALTRIALS.GOV, [ONLINE], 2017-05-29, [RETRIEVEDO, JPN6022031066, ISSN: 0004977527 *
PEDIATR. NEPHROL. (2015) VOL.30, ISSUE6, P.1033-1037, JPN6022031069, ISSN: 0004977528 *

Also Published As

Publication number Publication date
AU2018345625A1 (en) 2020-04-16
US20200262897A1 (en) 2020-08-20
WO2019070714A1 (en) 2019-04-11
JP2023101717A (ja) 2023-07-21
EP3692064A1 (en) 2020-08-12
US20240025975A1 (en) 2024-01-25
CN111278857A (zh) 2020-06-12
EP4424324A2 (en) 2024-09-04
CO2020004831A2 (es) 2020-05-29
BR112020006692A2 (pt) 2020-10-06
CA3078362A1 (en) 2019-04-11
EP4424324A3 (en) 2024-11-06
MX2020003619A (es) 2020-10-28
KR20200059279A (ko) 2020-05-28

Similar Documents

Publication Publication Date Title
US20240025975A1 (en) Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP7518764B2 (ja) 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
EP3914617B1 (en) Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
TW202237184A (zh) 抗cd19組合療法
JP2023533030A (ja) 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
CN116261569A (zh) 用于治疗包括狼疮性肾炎（LN）和/或IgA肾病（IgAN）的C5介导的肾小球肾炎（GN）的抗C5抗体的剂量和施用
RU2822664C2 (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
JP2023507852A (ja) 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
EA043233B1 (ru) ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131